XERSXeris Biopharma Holdings, Inc.

$960M

FY 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$164M+48.7% YoY

Gross Profit

$135M82.5% margin

Operating Income

-$44M-26.8% margin

Net Income

-$62M-38.0% margin

EPS (Diluted)

$-0.45

Cash Flow

Operating Cash Flow

-$47M

Free Cash Flow

-$49M

Stock-Based Comp.

$11M

Balance Sheet

Total Assets

$323M

Total Liabilities

$329M

Stockholders' Equity

-$7M

Cash & Equivalents

$67M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$164M	$110M	+48.7%
Gross Profit	$135M	$88M	+54.4%
Operating Income	-$44M	-$82M	+46.3%
Net Income	-$62M	-$95M	+34.2%

XERS FY 2023 Earnings — Xeris Biopharma Holdings, Inc. Revenue & Financial Results | Market Cap Arena